Sona Nanotech COVID-19 Antigen Rapid Saliva Test Device
Sona’s Antigen Rapid Saliva Test
The Sona Nanotech COVID-19 Saliva Lateral Flow Assay is an immunochromatographic assay for the qualitative detection of the spike protein antigen from SARS-CoV-2 in conveniently collected saliva specimens from individuals who are suspected of COVID-19.
Less invasive than current nasopharyngeal testing methods
Accessible and portable tool for Point-of-Care (POC) testing
No analyzer required for reading results
Results within 20 minutes
The test is ideal for use in a variety of scenarios, such as:
Testing of individuals for whom nasopharyngeal methods are uncomfortable or not possible
Children and the infirm
Screening patients who may be ready for release from quarantine
Determining the need for further testing/treatment in clinical/pharmacy settings and private long-term care facilities
Sona have partnered with US-based Arlington Scientific Inc. (ASI), an in-vitro diagnostics developer, manufacturer and distributor, to bring Sona’s rapid saliva COVID-19 test to market. Under the terms of the agreement, Sona licenses the intellectual property for its rapid saliva COVID-19 test and ASI undertakes to secure an FDA Emergency Use Authorization (“EUA”) for point-of-care and at-home use for the test and any necessary associated activities, including medical ethics review board approval, the coordination and underwriting of US-based clinical and any other studies, and FDA EUA application submissions and follow-up. If an FDA EUA is granted, Arlington will coordinate manufacturing and distribution of the test in the U.S. exclusively on a profit-sharing basis by which it would also earn a share of any of Sona’s profits from international sales.